Le Lézard
Classified in: Health, Science and technology
Subject: Award

SEQENS North America Picks up Six 2019 Life Science CMO Leaderships Awards


SEQENS North America (formerly PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it has won six 2019 Life Science Leader CMO Leadership Awards. The company won in every category: Quality, Capabilities, Compatibility, Expertise, Reliability, and Service across all three groups of respondents (Big Pharma, Small Pharma and Overall (combined Big and Small Pharma).

This is the fifth time in the CMO Leadership Awards program's eighth year that SEQENS has been awarded multiple awards, including across all six major categories. The company has now won 30 CMO Leadership Awards since 2014. The awards will be presented at The CMO Leadership Awards Reception at Convene, at 237 Park Avenue on March 20, 2019 in NYC.

For the 2019 CMO Leadership Awards, Life Science Leader magazine teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 120 contract manufactures were assessed by 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey. Survey participants were recruited from Pharma and Biopharma companies of all sizes and were screened for decision-making influence related to working with contract manufacturing suppliers. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with contract manufacturers and clear experiential data.

"Each year, the value that CMOs bring to individual biotech and pharma companies increases, as does the overall importance of the service sector to our entire and global drug development and manufacturing industry," said Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.

"Amid growing industry competition, the fact that SEQENS North America continues to win CMO Leadership Awards, especially across all categories, is a testament to our people, training and equipment as well as to our results-driven culture ? particularly since winners are based on input from people who work with us," said Ed Price, president and CEO of SEQENS North America. "While we're now known as SEQENS North America, part of a global CDMO that can offer more resources and even deeper expertise, our commitment to being responsive to our sponsors remains a core value."

SEQENS North America, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as APIs, has a portfolio of commercially approved products that now includes nine commercial products that either have or are imminently receiving FDA approval for sale in the U.S. The division has more than 17 API and other advanced materials products in its pipeline.

About SEQENS North America
SEQENS North America (formerly PCI Synthesis) is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass., a division of SEQENS, an integrated global leader in pharmaceutical synthesis and specialty ingredients with 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia.

SEQENS North America is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, SEQENS North America provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about SEQENS North America, its proprietary NCE development activities and process R&D capabilities please visit www.seqens.com.


These press releases may also interest you

at 06:35
HEXO Corp ("HEXO" or the "Company") plans to release its complete financial results for the quarter ended April 30, 2020, before market hours on Thursday, June 11th, 2020, as well as host a webcast for investors beginning at 8:30 a.m. EST. Webcast...

at 06:15
In honor of Pride Month, a month dedicated to recognizing the LGBTQ community, Shady Grove Fertility (SGF) is hosting two events to spread awareness about the multiple family building options available to the LGBTQ community. Tomer Singer, M.D., who...

at 06:05
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise. With the closing of Fund XII,...

at 06:05
Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it has resumed its pivotal study of Omnipod, Powered by Horizontm, the Company's...

at 06:00
U.S. Renal Care (USRC), a leading provider of dialysis services for patients living with kidney disease, announced today that it has named 25?year industry veteran, Mark Caputo, as Chief Executive Officer, following a national search of top tier...

at 06:00
Perception Health, a leading provider of data analytics and predictive intelligence for the healthcare market, announced today the addition of several executives to the management team....



News published on 11 march 2019 at 09:20 and distributed by: